Welcome to our dedicated page for Pure Bioscience SEC filings (Ticker: PURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PURE Bioscience, Inc. (OTCQB: PURE) SEC filings page provides access to the company’s official regulatory disclosures, offering a detailed view of its financial condition, governance, and capital structure. PURE files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements such as its definitive DEF 14A, along with other required documents.
In its periodic reports, PURE presents information on net product sales, royalty revenue, cost of goods sold, operating expenses, and net loss, as well as cash flows and financing activities, including convertible notes payable to related parties. Balance sheets detail assets, liabilities, and stockholders’ equity (deficiency), giving investors insight into liquidity, leverage, and accumulated deficit. These filings also describe the company’s focus on SDC-based antimicrobial products for food safety and the food and beverage industry.
Current reports on Form 8-K highlight material events, such as the release of quarterly and annual financial results and leadership changes, including the appointment of a President alongside existing executive roles. The definitive proxy statement on Schedule 14A outlines matters submitted to stockholders, including director elections, auditor ratification, advisory votes on executive compensation, and proposals to amend the certificate of incorporation, such as increasing authorized common shares.
On Stock Titan, PURE’s filings are updated as they are posted to the SEC’s EDGAR system. AI-powered tools summarize lengthy documents like 10-Ks and 10-Qs, explain key sections in plain language, and help surface items such as compensation details, related-party financing, and proposals affecting common stock. Users can also review 8-K items for recent corporate events and use the filing history to track how PURE’s financial position and governance decisions evolve over time.
PURE Bioscience (PURE) furnished an 8‑K under Item 2.02 announcing a press release with financial results for the fiscal year ended July 31, 2025. The press release is attached as Exhibit 99.1. The company states the information is being furnished, not filed, and will not be incorporated by reference into other SEC filings.